Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

CANF added a few more today for the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
swanlinbar Member Profile
 
Followed By 70
Posts 11,370
Boards Moderated 9
Alias Born 08/09/00
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/30/2020 7:08:57 AM
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Business Wire - 6/30/2020 7:00:00 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 6/19/2020 4:36:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 4:24:38 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 6:03:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2020 8:30:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:04:03 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 8:11:22 AM
Can-Fite Announces $8.0 Million Registered Direct Offering Business Wire - 6/10/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/9/2020 7:05:20 AM
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. Business Wire - 6/9/2020 7:00:00 AM
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 Business Wire - 6/8/2020 7:25:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2020 7:22:28 AM
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial & Registration Plan for ... Business Wire - 6/4/2020 7:14:00 AM
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th Business Wire - 6/3/2020 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/1/2020 7:24:12 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 7:07:32 AM
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update Business Wire - 6/1/2020 7:00:00 AM
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 Business Wire - 5/28/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 7:13:58 AM
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent & Trademark Of... Business Wire - 5/21/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/18/2020 7:09:21 AM
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liv... Business Wire - 5/18/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/15/2020 7:29:18 AM
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Modera... Business Wire - 5/15/2020 7:00:00 AM
swanlinbar   Monday, 05/18/20 12:56:35 PM
Re: None
Post # of 1449 
CANF added a few more today for the Long haul Can-Fite BioPharma Up 18.5%; Reports Additional Findings From Phase II Study
7:27 am ET May 18, 2020 (Dow Jones) Print
By Michael Dabaie

Can-Fite BioPharma Ltd. shares were up 18.5%, to $2.18, in premarket trading.

The company Monday unveiled additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis.

The company in April reported topline results from the Phase II study indicating Namodenoson had achieved its efficacy endpoints in a dose dependent and statistically significant manner.

The company said a more recent in-depth review of the Phase II data showed 25 mg of Namodenoson was found to resolve significantly all cases of NASH, representing 25% of the 25 mg treated group.

In the Phase II study, 25 mg of Namodenoson was shown to reduce hepatic fibrosis, or scar tissue in the liver resulting from the liver trying to repair itself, reduce fat buildup in the liver, and improve the FAST score, a measure for NASH, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

"that a rich man is not the one who has the most but the one who needs the least"
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist